Kailera Therapeutics (KLRA) investor relations material

Company overview and business model

• Advanced clinical-stage biotechnology company focused on obesity care with a diversified pipeline targeting various stages of the obesity treatment journey.

• Lead product candidate is ribupatide, a once-weekly injectable GLP-1/GIP receptor dual agonist in global Phase 3 trials, aiming for superior weight loss efficacy.

• Pipeline includes oral ribupatide, KAI-7535 (oral small molecule GLP-1 agonist), and KAI-4729 (injectable GLP-1/GIP/glucagon tri-agonist).

• Holds exclusive worldwide rights (excluding Greater China) to all product candidates through a strategic collaboration with Hengrui.

• Business model leverages in-licensed assets, capital-efficient development, and plans for broad commercial reach and manufacturing scale.

Financial performance and metrics

• No revenue generated to date; net losses of $219.7 million (2024) and $149.0 million (2025); accumulated deficit of $368.7 million as of December 31, 2025.

• Operating expenses: $230.4 million (2024), $158.3 million (2025), with R&D expenses increasing to $109.1 million in 2025.

• Cash, cash equivalents, and marketable securities of $652.7 million as of December 31, 2025.

• Raised $900 million from leading life science investors, including Bain Capital, RTW Investments, Atlas Venture, and CPP Investments.

• Expects current cash and IPO proceeds to fund operations into the future but will require additional capital for full development and commercialization.

Use of proceeds and capital allocation

• Net proceeds from IPO to fund development of ribupatide, oral ribupatide, KAI-7535, and KAI-4729, as well as other R&D activities, working capital, and general corporate purposes.

• Management retains broad discretion over allocation; may use a portion for in-licensing, acquisitions, or investments in additional assets.